Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris : ALVIO), ci-après « Valerio Therapeutics » ou « la Société », société de...
The first dose level, evaluating 3 patients of the VIO-01-101 trial has been cleared as per the recommendations of the Clinical Review...
Cash position of €6.8 million as of December 31, 2023 Financial visibility until the end of fourth quarter of 2024 Regulatory News: Valerio...
Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO), hereafter “Valerio Therapeutics” or the “Company”, a clinical-stage...
Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO) Under the liquidity contract entered into between Valerio Therapeutics...
New identity unveiled, with the aim at developing innovative therapies against cancer R&D efforts maintained for VIO-01 (formerly OX425) and...
Regulatory News: Au titre du contrat de liquidité confié par la société VALERIO THERAPEUTICS (Paris:ALVIO) à Kepler Cheuvreux, à la date du 30...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.